Hong-Zhi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hong-Zhi Wang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Huan-Xin Lin
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
1 shared publication - Hui Lin
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangdong Province, Guangzhou 510060, China
1 shared publication - Nan Ge
Surgical Intensive Care Unit, Xiangtan Central Hospital, Hunan Province, Xiangtan, 411100, China
1 shared publication - Rui Sun
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
1 shared publication - Wei-Han Hu
State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University, Guangzhou
1 shared publication
Latest Publications
- Open Access
- 15 May 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 121
Plasma uric acid and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy
Background: The combined predictive value of plasma uric acid and primary tumor volume in nasopharyngeal carcinoma (NPC) patients receiving intensity modulated radiation therapy (IMRT) has not yet been determined. Methods: In this retrospective study, plasma uric acid level was measured after treatment in 130 histologically-proven NPC patients treated with IMRT. Tumor volume was calculated from treatment planning CT scans. Overall (OS), progression-free (PFS) and distant metastasis-free (DMFS) survival were compared using Kaplan-Meier analysis and the log rank test, and Cox multivariate and univariate regression models were created. Results: Patients with a small tumor volume (301 μmol/L) had a better DMFS, PFS and OS than patients with a low post-treatment plasma uric acid level. Patients with a small tumor volume and high post-treatment plasma uric acid level had a favorable prognosis compared to patients with a large tumor volume and low post-treatment plasma uric acid level (7-year overall OS, 100% vs. 48.7%, P P <0.001). Conclusions: Post-treatment plasma uric acid level and pre-treatment tumor volume have predictive value for outcome in NPC patients receiving IMRT. NPC patients with a large tumor volume and low post-treatment plasma uric acid level may benefit from additional aggressive treatment after IMRT.
- 15 May 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 121
Open AccessPlasma uric acid and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy
Background: The combined predictive value of plasma uric acid and primary tumor volume in nasopharyngeal carcinoma (NPC) patients receiving intensity modulated radiation therapy (IMRT) has not yet been determined. Methods: In this retrospective study, plasma uric acid level was measured after treatment in 130 histologically-proven NPC patients treated with IMRT. Tumor volume was calculated from treatment planning CT scans. Overall (OS), progression-free (PFS) and distant metastasis-free (DMFS) survival were compared using Kaplan-Meier analysis and the log rank test, and Cox multivariate and univariate regression models were created. Results: Patients with a small tumor volume (301 μmol/L) had a better DMFS, PFS and OS than patients with a low post-treatment plasma uric acid level. Patients with a small tumor volume and high post-treatment plasma uric acid level had a favorable prognosis compared to patients with a large tumor volume and low post-treatment plasma uric acid level (7-year overall OS, 100% vs. 48.7%, P P <0.001). Conclusions: Post-treatment plasma uric acid level and pre-treatment tumor volume have predictive value for outcome in NPC patients receiving IMRT. NPC patients with a large tumor volume and low post-treatment plasma uric acid level may benefit from additional aggressive treatment after IMRT.